Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424538 | 0.89 | IDO1 (0.46) | LMNASMN1; SMN2ALDH1A1IDO1TDO2 | |
| SCHEMBL11820501 | 0.87 | TSHR (0.61) | TSHRLMNAHPGDALDH1A1IDO1 | |
| SCHEMBL151375 | 0.84 | TSHR (0.65) | TSHRLMNAHPGDALDH1A1KDM4E | |
| Bromide SCHEMBL21831069 | 0.81 | TSHR (0.61) | TSHRLMNAHPGDALDH1A1KDM4E | |
| Hydrogen Sulfide SCHEMBL21379318 | 0.81 | TSHR (0.61) | TSHRLMNAHPGDALDH1A1KDM4E | |
| SCHEMBL10639836 | 0.80 | TSHR (0.48) | TSHRLMNAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL21367678 | 0.79 | SLC6A2 (0.50) | LMNAHPGDSMN1; SMN2HTTUSP2 | |
| SCHEMBL3690196 | 0.79 | SLC6A2 (0.50) | LMNAHPGDSMN1; SMN2HTTUSP2 | |
| SCHEMBL12880582 | 0.79 | TSHR (0.52) | TSHRHPGDUSP2ALDH1A1NPSR1 | |
| SCHEMBL11201293 | 0.78 | ACHE (0.62) | LMNASMN1; SMN2ALDH1A1NFE2L2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059950-A | Compounds with proteasome agonistic activity, preparation method and application thereof | 浙大城市学院 | 2026-05-19 | — | — | CN | disclosed |
| CN-118307456-A | Coniferyl aldehyde derivative containing dithioacetal unit, and preparation method and application thereof | 贵州大学 | 2024-07-09 | — | — | CN | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| WO-1994003436-A1 | NOVEL PIPRAZINE CARBOXAMIDES | KABI PHARMACIA AB (SE) | 1994-02-17 | — | — | WO | disclosed |
| WO-1994003430-A1 | NOVEL PYRIDYL- AND PYRIMIDYLPIPERAZINE DERIVATIVES | KABI PHARMACIA AB (SE) | 1994-02-17 | — | — | WO | disclosed |
| US-5153207-A | Antihistamine and antiallergic agent | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0399414-A1 | Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-28 | — | — | EP | disclosed |
| US-4874765-A | 1,4-Disubstituted piperazines having dopaminergic activity | RICHTER GEDEON VEGYESZETI GYAR (HU) | 1989-10-17 | — | — | US | disclosed |
| EP-0243903-A1 | Optionally substituted 1-(omega[bis(phenyl)-alcoxy]-alkyl)-4-(alkenyl)piperazines and -4-(alkynyl)piperazines, process for their preparation and medicines containing them | Richter Gedeon Vegyészeti Gyár R.T. (HU) | 1987-11-04 | — | — | EP | disclosed |
| US-4088763-A | VASCULAR AND CARDIAC DISEASES | KNOLL A.G. CHEMISCHE FABRIKEN (DT) | 1978-05-09 | — | — | US | disclosed |
| US-4079137-A | FOR TREATMENT OF VASCULAR AND CARDIAC DISEASES | KNOLL A.G. CHEMISCHE FABRIKEN (DT) | 1978-03-14 | — | — | US | disclosed |
| US-4017631-A | MICROBIOCIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-04-12 | — | — | US | disclosed |
| US-3991202-A | ANTIMICROBIALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | TSHR 428/4885LMNA 2792/4885HPGD 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.